Institut’ DERMed Clinical Skincare announced their innovative product line now includes an advanced anti-aging serum that will stimulate collagen production and prevent free radical damage for a youthful complexion.
The Anti- Oxidant Peptide Serum is formulated with Pro-Coll-One Peptides and Apple Stem Cells. This cutting-edge skin care product will increase epidermal hydration while accelerating new cell growth and reducing skin stress and potential complications from environmental conditions.
Pro-Coll-One Peptides derived from soya, contain highly purified glycopeptides which boost production of collagen 1 synthesis. Studies have shown a consolidation of the dermal mattress significantly reduce wrinkles and smooth the skin’s surface.
The Apple Stem cells, derived from the UTTwiler Spatlauber, an apple known for its longevity, is the first plant stem cell active ingredient on the market whose effect has been evaluated on human skin stem cells. Results show that when the stem cell extract is applied to epidermal stem cells they regain their capacity to form a stratified 3D epidermis supporting skin rejuvenation.
This cutting-edge skin care product will increase epidermal hydration while accelerating new cell growth and reducing skin stress and potential complications from environmental conditions.
“Clinical trials with Uttwiler Spatlauber stem cells showed a significant reduction in wrinkle depth after two to four weeks,” stated Lyn Ross, Founder of Institut’ DERMed. “I’m extremely excited to be adding these ingredients to the Institut’ DERMed anti-aging product arsenal.”
The Anti-Oxidant Peptide serum is now available for purchase at select spas nationwide, online at idermedstore.com.
See Also: Institut’ DERMed Chromabright SerumCollagenna Professional Strength Peptide with Hyaluronic AcidChanel New Anti Aging SerumJanet Sartin Advanced Anti-Wrinkle Peptide Serum for All Skin TypesYour Guide to Beautiful Skin at Any Age
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
No comments:
Post a Comment